Small font size A Larger text size A Largest text size A

Revolution Medicines Closes Concurrent Public Offerings of Shares, Notes

BY MT Newswires | CORPORATE | 04/17/26 04:22 PM EDT

04:22 PM EDT, 04/17/2026 (MT Newswires) -- Revolution Medicines (RVMD) said late Friday it has closed its concurrent upsized public offerings of 12.1 million common shares at a public offering price of $142 apiece and $500 million of 0.50% convertible senior notes due 2033 for collective gross proceeds of about $2.23 billion.

The offering included nearly 1.6 million shares issued upon exercise in full by the underwriters of their option to buy additional shares, the company said.

The notes will mature on May 1, 2033, unless earlier repurchased, redeemed or converted, according to the company.

Revolution Medicines (RVMD) said it plans to use the net proceeds from the offerings for general corporate purposes.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

China's factory activity remains in expansion in April, PMI shows BY Reuters |ECONOMIC 09:35 PM EDT
Dollar holds firm after Fed raises inflation alarm, yen slips past 160 BY Reuters |ECONOMIC 09:25 PM EDT
FOREX-Dollar holds firm after Fed raises inflation alarm, yen slips past 160 BY Reuters |ECONOMIC 09:21 PM EDT
Japan March industrial production falls on chemical output decline BY Reuters |ECONOMIC 08:45 PM EDT

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article